BG104871A - Полиол - интерферон - бета конюгати - Google Patents

Полиол - интерферон - бета конюгати

Info

Publication number
BG104871A
BG104871A BG104871A BG10487100A BG104871A BG 104871 A BG104871 A BG 104871A BG 104871 A BG104871 A BG 104871A BG 10487100 A BG10487100 A BG 10487100A BG 104871 A BG104871 A BG 104871A
Authority
BG
Bulgaria
Prior art keywords
beta
ifn
peg
conuggates
interferon
Prior art date
Application number
BG104871A
Other languages
English (en)
Other versions
BG64694B1 (bg
Inventor
Tayar Nabil El
Michael Roberts
Milton Harris
Wayne Sawlivich
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of BG104871A publication Critical patent/BG104871A/bg
Publication of BG64694B1 publication Critical patent/BG64694B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до получаване на ПЕГ-IFN-бета конюгати, в които ПЕГ остатъкът е ковалентно свързан с Cys17 от човешки интерферон-бета чрез метод на сайтово специфично пегилиране с тиолно реактивоспособни пегилиращи агенти, до фармацевтичен препарат и до метод за лечение на инфекции, тумори и автоимунни и възпалителни заболявания. Изобретението се отнася и до метод за степенно прикрепване в серии на ПЕГ остатъци към полипептид и по-специално към интерферон-бета.
BG104871A 1998-04-28 2000-10-17 Полиол - интерферон - бета конюгати BG64694B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28

Publications (2)

Publication Number Publication Date
BG104871A true BG104871A (bg) 2001-07-31
BG64694B1 BG64694B1 (bg) 2005-12-30

Family

ID=22177687

Family Applications (2)

Application Number Title Priority Date Filing Date
BG109291A BG65046B1 (bg) 1998-04-28 2000-10-17 Метод за степенно прикрепване на полиетиленгликолкъм полипептид
BG104871A BG64694B1 (bg) 1998-04-28 2000-10-17 Полиол - интерферон - бета конюгати

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG109291A BG65046B1 (bg) 1998-04-28 2000-10-17 Метод за степенно прикрепване на полиетиленгликолкъм полипептид

Country Status (30)

Country Link
US (3) US6638500B1 (bg)
EP (2) EP1075281B1 (bg)
JP (2) JP4574007B2 (bg)
KR (1) KR100622796B1 (bg)
CN (2) CN1187094C (bg)
AR (1) AR020070A1 (bg)
AT (2) ATE365563T1 (bg)
AU (1) AU762621B2 (bg)
BG (2) BG65046B1 (bg)
BR (1) BR9910023A (bg)
CA (2) CA2330451A1 (bg)
CY (1) CY1108022T1 (bg)
CZ (2) CZ298579B6 (bg)
DE (2) DE69936409T2 (bg)
DK (2) DK1075281T3 (bg)
EA (2) EA200300382A1 (bg)
EE (1) EE05214B1 (bg)
ES (2) ES2285286T3 (bg)
HU (1) HUP0300548A3 (bg)
IL (1) IL139286A (bg)
NO (2) NO329749B1 (bg)
NZ (1) NZ507456A (bg)
PL (2) PL196533B1 (bg)
PT (2) PT1075281E (bg)
SI (2) SI1075281T1 (bg)
SK (2) SK286217B6 (bg)
TR (2) TR200003161T2 (bg)
TW (2) TWI266800B (bg)
UA (2) UA66857C2 (bg)
WO (1) WO1999055377A2 (bg)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
KR100669053B1 (ko) * 1999-04-23 2007-01-15 알자 코포레이션 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
TR200101086A3 (bg) * 1999-10-15 2001-08-21
AU2223401A (en) 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Branched polyalkylene glycols
SK11672002A3 (sk) 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
WO2002060978A1 (en) 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
EP2080771A3 (en) 2001-02-27 2010-01-06 Maxygen Aps New interferon beta-like molecules
PL371781A1 (en) 2001-07-11 2005-06-27 Maxygen Holdings, Ltd. G-csf conjugates
EE05509B1 (et) 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EA008866B1 (ru) 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
DK1608745T3 (da) 2003-03-20 2009-06-15 Bayer Healthcare Llc FVII eller FVIIa-Varianter
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP2327724A3 (en) * 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
JP2007538048A (ja) 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
EP1750750B1 (en) 2004-06-01 2012-02-01 Ares Trading S.A. Method of stabilizing proteins
UA92146C2 (ru) 2004-06-01 2010-10-11 Эйрэс Трейдинг С.А. Стабилизированная жидкая композиция, которая содержит интерферон
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
ATE494012T1 (de) † 2004-12-21 2011-01-15 Nektar Therapeutics Stabilisierte polymer-thiol-reagenzien
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
GB2438760A (en) 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
MX2008001706A (es) * 2005-08-04 2008-04-07 Nektar Therapeutics Al Corp Conjugados de una porcion g-csf y un polimero.
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2444499A3 (en) * 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
BRPI0821029A2 (pt) * 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
EP2616486B1 (en) 2010-09-15 2019-01-02 Stichting Sanquin Bloedvoorziening Factor viii variants having a decreased cellular uptake
US9913880B2 (en) 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP6153470B2 (ja) * 2011-10-01 2017-06-28 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2013129549A1 (ja) 2012-02-29 2013-09-06 東レ株式会社 体腔液貯留抑制剤
ES2687801T3 (es) 2013-03-29 2018-10-29 Glytech, Inc. Polipéptido presentando cadenas de azúcares sialiladas unidas al mismo
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
SI3183264T1 (sl) 2014-08-19 2021-03-31 Biogen Ma Inc. Metoda pegilacije
CN107530396B (zh) 2015-05-01 2022-08-26 雅利斯塔制药公司 用于治疗眼科疾病的脂联素拟肽
HRP20201489T1 (hr) * 2015-06-19 2020-12-11 Eisai R&D Management Co., Ltd. Imunoglobulini konjugirani s cys80
EP3373922B1 (en) 2015-11-09 2022-01-05 The Regents of The University of Colorado, A Body Corporate Compositions and methods for use in the treatment of homocystinuria
EP3612214A4 (en) * 2017-04-17 2021-01-20 The Regents of the University of Colorado, A Body Corporate ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA
EP3713582A1 (en) 2017-11-24 2020-09-30 Merck Patent GmbH Cladribine regimen for use intreating progressive forms of multiple sclerosis
JPWO2020158691A1 (ja) 2019-01-28 2021-12-02 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
JPWO2020158690A1 (ja) 2019-01-28 2021-12-16 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR960705579A (ko) 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
CN1229385C (zh) * 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
ES2245780T3 (es) * 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
DE69800640T2 (de) * 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
EA200001111A1 (ru) 2001-04-23
PL196533B1 (pl) 2008-01-31
IL139286A0 (en) 2001-11-25
CN100335503C (zh) 2007-09-05
SK286654B6 (sk) 2009-03-05
EA005495B1 (ru) 2005-02-24
DE69936409T2 (de) 2008-04-17
WO1999055377A3 (en) 1999-12-29
CZ20003995A3 (en) 2001-06-13
CN1637020A (zh) 2005-07-13
NO329749B1 (no) 2010-12-13
JP2010184929A (ja) 2010-08-26
US7700314B2 (en) 2010-04-20
CZ298597B6 (cs) 2007-11-21
US6638500B1 (en) 2003-10-28
DE69936409D1 (de) 2007-08-09
SI1075281T1 (en) 2005-02-28
ES2224649T3 (es) 2005-03-01
KR20010071158A (ko) 2001-07-28
SI1421956T1 (sl) 2007-10-31
CA2565375A1 (en) 1999-11-04
BR9910023A (pt) 2000-12-26
DE69920002T2 (de) 2005-09-22
CZ298579B6 (cs) 2007-11-14
PL344490A1 (en) 2001-11-05
AR020070A1 (es) 2002-04-10
EA200300382A1 (ru) 2005-02-24
JP2002512983A (ja) 2002-05-08
BG64694B1 (bg) 2005-12-30
ATE365563T1 (de) 2007-07-15
AU3767499A (en) 1999-11-16
EP1421956A1 (en) 2004-05-26
SK16222000A3 (sk) 2001-04-09
NO20005337D0 (no) 2000-10-23
KR100622796B1 (ko) 2006-09-13
PL193352B1 (pl) 2007-02-28
BG65046B1 (bg) 2007-01-31
WO1999055377A9 (en) 2000-03-02
HK1038194A1 (zh) 2002-03-08
SK286217B6 (sk) 2008-05-06
PT1075281E (pt) 2004-11-30
TR200101751T2 (tr) 2002-05-21
TWI232882B (en) 2005-05-21
TR200003161T2 (tr) 2001-01-22
NO20100324L (no) 2000-12-28
CN1187094C (zh) 2005-02-02
IL139286A (en) 2005-12-18
CN1302209A (zh) 2001-07-04
DE69920002D1 (de) 2004-10-14
HUP0300548A3 (en) 2005-07-28
NO20005337L (no) 2000-12-28
US20040043002A1 (en) 2004-03-04
CY1108022T1 (el) 2013-09-04
EP1421956B1 (en) 2007-06-27
TWI266800B (en) 2006-11-21
NO332224B1 (no) 2012-07-30
ATE275422T1 (de) 2004-09-15
HUP0300548A2 (hu) 2003-06-28
EA003789B1 (ru) 2003-10-30
UA66857C2 (uk) 2004-06-15
WO1999055377A2 (en) 1999-11-04
US20070141620A1 (en) 2007-06-21
DK1075281T3 (da) 2005-01-03
JP4574007B2 (ja) 2010-11-04
PT1421956E (pt) 2007-07-13
CA2330451A1 (en) 1999-11-04
NZ507456A (en) 2003-10-31
DK1421956T3 (da) 2007-10-01
HK1076115A1 (zh) 2006-01-06
BG109291A (bg) 2006-04-28
AU762621B2 (en) 2003-07-03
UA79430C2 (en) 2007-06-25
EE05214B1 (et) 2009-10-15
EP1075281B1 (en) 2004-09-08
ES2285286T3 (es) 2007-11-16
EP1075281A2 (en) 2001-02-14
EE200000614A (et) 2002-04-15
US7357925B2 (en) 2008-04-15

Similar Documents

Publication Publication Date Title
BG104871A (bg) Полиол - интерферон - бета конюгати
ATE297762T1 (de) Peg-lhrh analog konjugate
CA2158054A1 (en) Conjugates of proteins and bifunctional ligands
NO901986L (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
MX9700552A (es) Conjugados de vitamina b12 y proteinas.
LU92237I2 (fr) Pegloticase et toute forme thérapeutique équivalente protégée par le brevet de base
BG101030A (bg) Лечение на атеросклероза и на други кардиоваскуларни и възпалителни заболявания
WO2003022210A3 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
FI963103A0 (fi) Ei-virusvektori
CA2345027A1 (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
ATE335719T1 (de) Polyamine und ihre therapeutische verwendung
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
HU911929D0 (en) Process for the production of conjugates containing orto ligating functional group from chelate complexes and joint antibodies or antibody fragments and the medical preparations containing thereof
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
TR199902775T2 (xx) 20(S)-Kamptotesin glikokonjugeleri.
TWI266801B (en) Polyol-IFN-beta conjugates
FI933506L (fi) Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaatteja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina
TW200643029A (en) Pegylated interferon alpha-1B